|
| Author (year) | Clinical evaluation method | GKRS max dose (Gy) | Study endpoints | Results |
|
| | | BNI scores of I–IIIb at 1-y for idiopathic TN | 75% |
| | | BNI scores of I–IIIb at 3-y for idiopathic TN | 60% |
| | | BNI scores of I–IIIb at 5-y for idiopathic TN | 58% |
| Verheul et al. [33] (2010) | BNI | 1st treatment: 80
2nd treatment: 80 | BNI scores of I–IIIb at 1-y for MS-related TN | 56% |
| BNI scores of I–IIIb at 3-y for MS-related TN | 30% |
| | | BNI scores of I–IIIb at 5-y for MS-related TN | 20% |
| | | 5-y idiopathic retreatment pain relief rate | 75% |
| | | 5-y MS retreatment pain relief rate | 46% |
|
| | | Pain outcome in primary versus secondary GKRS | P = NS |
| Park et al. [34] (2011) | BNI | 1st treatment mean: 82.4 ± 6.25
2nd treatment mean: 81 ± 4.89 | Primary GKRS facial numbness | 21% |
| | | Secondary GKRS facial numbness | 45.8% |
|
| | | BNI score of I–III at 1-y | 75% |
| | | Patients requiring additional surgery | 41% |
| Little et al. [35] (2009) | BNI | 1st treatment: 80
2nd treatment: 40–50 | Patients with mild facial numbness | 76% |
| | | Patients with bothersome facial numbness | 8% |
| | | Patients with eye symptoms | 12% |
|
| | | BNI scores of I–IIIb at 1-y | 82.6% |
| Zorro et al. [3] (2009) | BNI | Median: 80 | BNI scores of I–IIIb at 3-y | 73.9% |
| BNI scores of I–IIIb at 5-y | 54% |
| | | Patients with facial sensory dysfunction | 5.4% |
|
| | | 1-y no previous treatment excellent outcome rate | 82.5% |
| | | 1-y previous treatment excellent outcome rate | 69.4% |
| Fountas et al. [36] (2007) | EGFP | Median: 80 | 2-y no previous treatment excellent outcome rate | 78% |
| 2-y previous treatment excellent outcome rate | 63.5% |
| | | No previous treatment paresthesia rate | 15.8% |
| | | Previous treatment paresthesia rate | 16.3% |
|
| | | 1-y no previous treatment excellent outcome rate | 80.8% |
| | | 1-y previous treatment excellent outcome rate | 69.2% |
| Fountas et al. [37] (2006) | EGFP | Median: 80 | 2-y no previous treatment excellent outcome rate | 64% |
| 2-y previous treatment excellent outcome rate | 11.5% |
| | | No previous treatment facial numbness rate | 17.3% |
| | | Previous treatment facial numbness rate | 16% |
|
| | | 1st treatment excellent outcome rate | 56% |
| | | 1st treatment good outcome rate | 13.5% |
| Huang et al. [38] (2008) | EGFP | 1st treatment mean: 79
2nd treatment mean: 52 | 1st treatment fair outcome rate | 7.9% |
| 2nd treatment excellent outcome rate | 55% |
| | | 2nd treatment good outcome rate | 5% |
| | | Facial numbness associated with repeat GKRS | P = 0.007 |
|
|
Huang et al. [39] (2008) | EGFP | Mean: 60.7 | Excellent outcome rate after GKRS to the tumor | 57% |
| Excellent outcome rate after GKRS to CN V | 50% |
|
